The dismissals are based on Jan Marini and Intuit Beauty acknowledging the validity of Allergan's relevant patents covering the use of certain drug substances, such as prostaglandin analogs, to promote eyelash enhancement and also agreeing to cease their distribution of eyelash products containing these ingredients in the United States and other countries worldwide where Allergan owns related patents. On July 2, 2007, Allergan completed the sale of the ophthalmic surgical business that Allergan obtained in connection with its January 2007 acquisition of Groupe Corneal Laboratoires. Amgen's Second Quarter 2008 Adjusted Earnings Per Share Increased 2 Percent to $1. Amgen's Fourth Quarter 2007 Adjusted Earnings Per Share (EPS) Increased 11 Percent to $1. Amgen's First Quarter 2008 Adjusted Earnings Per Share Increased 4 percent to $1. read more